Galux Selected for Korea Credit Guarantee Fund's Pre-ICON Program, Eligible for Up to 7 Billion Won in Guarantees
Advance AI Protein Design Platform and Develop Proprietary Drug Pipelines
Funds to Expand GPU and Computing Infrastructure and Recruit Key Research Personnel
Galux, an artificial intelligence (AI) drug discovery company, announced on Nov. 3 that it had been selected for the Korea Credit Guarantee Fund’s Pre-ICON program, which helps promising innovative companies scale up. With this selection, Galux will be eligible for guarantee support of up to 7 billion won.
Pre-ICON is a Korea Credit Guarantee Fund program that supports the growth of promising startups with strong technological capabilities, market potential and growth prospects. Galux plans to use its selection to advance its proprietary AI protein design platform, GaluxDesign, and expand research and development, including the development of its own drug pipelines.
Photo commemorating the selection for the Korea Credit Guarantee Fund's Pre-ICON program. From left: Lee Hyeongyeol, center director at the Korea Credit Guarantee Fund; Seok Chaok, CEO of Gallux; and Park Taeyong, CEO of Gallux. Gallux
View original imageGalux is developing AI technology that analyzes protein structures and molecular interactions based on physicochemical principles and designs proteins and antibodies needed for drug discovery. Rather than focusing solely on creating candidates that bind to specific targets, the company aims to account for factors such as binding affinity, stability and developability from the initial design stage.
The company said it recorded an average antibody-binding success rate of more than 30% using 50 AI-designed candidates for each target. It also said that, in a comparison based on nine targets disclosed by U.S. companies Nabla Bio and Chai Discovery, it obtained experimentally validated antibodies for eight of them.
Building on its protein design technology, Galux is expanding collaborative research with domestic and international pharmaceutical and biotechnology companies while developing its own drug pipelines. Its proprietary pipelines include a bispecific antibody immuno-oncology drug targeting PD-1 and IL-18.
Galux plans to use the funds secured through the guarantee support to expand its graphics processing unit (GPU) and computing infrastructure for AI model development, strengthen its experimental research environment and recruit key research personnel. The company aims to broaden the applications of its AI protein design technology and accelerate the development of its own drug candidates.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
“What matters in AI protein design is not simply generating a large number of candidates, but how precisely we can design molecules with the desired properties so they can be developed into actual drugs,” said Seok Chaok, CEO of Galux. “With this selection for Pre-ICON, we will accelerate the development of our core technologies and proprietary pipelines, strengthen our global competitiveness and broaden the possibilities for developing new treatments.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.